Chief Accounting Officer Justin Burgess unloads shares of Dynavax Technologies.

1 min read


  • Chief Accounting Officer, Justin Burgess, sold 20,526 shares of Dynavax on March 1, 2024.
  • The insider trend shows a total of 19 insider sells and no insider buys at the company over the past year.

Key Elements:

In a recent SEC filing, it was revealed that the Chief Accounting Officer of Dynavax Technologies Corp, Justin Burgess, sold 20,526 shares of the company on March 1, 2024, at a price of $12.78 per share. This transaction amounted to approximately $262,332.

Dynavax Technologies Corp is a biopharmaceutical company known for its focus on utilizing the body’s immune responses through toll-like receptor stimulation. Their flagship product, HEPLISAV-B, is a hepatitis B vaccine approved for adults aged 18 and older. The company also has clinical development programs for vaccines targeting infectious diseases and cancer immunotherapy.

Over the past year, Justin Burgess has sold a total of 28,587 shares of Dynavax Technologies Corp and has not made any share purchases. This selling trend is reflected in the company’s overall insider activity, with a total of 19 insider sells and no insider buys reported during the same period.

On the valuation front, Dynavax Technologies Corp’s shares were trading at $12.78 at the time of the insider’s sale, giving the company a market capitalization of $1.664 billion. The stock’s price-to-GF-Value ratio stands at 1.62, indicating that the shares are significantly overvalued based on the GF Value metric.

Investors and analysts often pay attention to insider transactions as they can provide insights into a company’s internal view on the stock’s valuation and future prospects. The consistent pattern of insider sales at Dynavax Technologies Corp may be of interest to stakeholders and potential investors.

It’s important to note that the article is designed to offer general insights based on historical data and analyst projections, and does not constitute personalized financial advice. The analysis does not recommend specific buy or sell actions and does not consider individual investment goals or financial situations.

Previous Story

ISCA teams up with PICPA to groom Filipino accountants.

Next Story

Downer EDI takes legal action against KPMG for accounting errors.

Latest from News

The unfair accounting system

TLDR: Article discusses the inequity method of accounting Highlights the importance of understanding this method for financial reporting The inequity method of accounting The